ライフサイエンスコーパス: specific immunity

1 arly after antigen challenge retards antigen-specific immunity.

2 tion of whether soluble CEA influences tumor-specific immunity.

3 ization with ASPH-loaded DCs induced antigen-specific immunity.

4 ses to HIV-1 Ags despite the presence of Ad5-specific immunity.

5 s radiotherapy-induced mobilization of tumor-specific immunity.

6 e pathogen can infect), innate immunity, and specific immunity.

7 mor-associated antigens, resulting in cancer-specific immunity.

8 activation, which may limit induction of RSV-specific immunity.

9 assessed for their ability to elicit antigen-specific immunity.

10 strategy to potentiate DC activation of HIV-specific immunity.

11 recognition of pathogens, leading to strain-specific immunity.

12 mmunopathogenic in cancers by impeding tumor-specific immunity.

13 the studies of HIV-1 pathobiology and virus-specific immunity.

14 kin 4 (IL-4) in the regulation of mycoplasma-specific immunity.

15 cells, no patients developed impaired virus-specific immunity.

16 either preexisting or vaccine-induced vector-specific immunity.

17 ion, suggesting a protective role for strain-specific immunity.

18 of the chemotherapy doses that maximize HER2-specific immunity.

19 fection, before the typical onset of antigen-specific immunity.

20 lerance induction in other models of antigen-specific immunity.

21 onse or the time to detection of HPV16/18 E7-specific immunity.

22 induced both humoral and cellular antigenic specific immunity.

23 r memory cell lineage development and tissue-specific immunity.

24 hat chemotherapy enhances tumor antigen (TA)-specific immunity.

25 Compared to CAs, AAs have weaker HCV-specific immunity.

26 kinase activity was absolutely required for specific immunity.

27 help B cell responses and promote influenza-specific immunity.

28 CMV viremia did not appear to boost CMV-specific immunity.

29 athogens and directing the development of Ag-specific immunity.

30 Rs for the development of posttransplant CMV-specific immunity.

31 minate various large tumors and induce tumor-specific immunity.

32 rvival and persistence of systemic ovalbumin-specific immunity.

33 latory T (T reg) cells that suppress antigen-specific immunity.

34 reassortant vaccines predicated on serotype-specific immunity.

35 llenge, and the apparent maturation of virus-specific immunity.

36 une response but also dampen foreign antigen specific immunity.

37 lls (DC) is critical for the induction of Ag-specific immunity.

38 diated cell transformation, and modulate EBV-specific immunity.

39 pecific tolerance while maintaining pathogen-specific immunity.

40 ar adjuvant and potentially promoting tissue-specific immunity.

41 myosin and myoglobin did not induce T. cruzi-specific immunity.

42 design of novel molecules for invoking tumor-specific immunity.

43 lastoma and generates systemic neuroblastoma-specific immunity.

44 omas, regression is known to involve antigen-specific immunity.

45 the efferent lymphatics that may enhance Ag-specific immunity.

46 en established for the reconstitution of EBV-specific immunity.

47 replication, but it is unable to restore HIV-specific immunity.

48 s a key role in the development of influenza-specific immunity.

49 mmune mechanisms are important for cruzipain-specific immunity.

50 nships among different parameters of antigen-specific immunity.

51 n production and may thus activate T. gondii-specific immunity.

52 ts that are not entirely dependent on intact specific immunity.

53 vivo and in vivo to initiate and enhance HIV-specific immunity.

54 A-BN-Filo resulted in sustained elevation of specific immunity.

55 their capacity to initiate and amplify tumor-specific immunity.

56 DC1 migration and function, likely hindering specific immunity.

57 APCs play a key role in the induction of Ag-specific immunity.

58 nt APCs that are capable of generating tumor-specific immunity.

59 role in the generation of protective antigen-specific immunity.

60 romising combination for stimulating antigen-specific immunity.

61 this might not reflect alterations in tissue-specific immunity.

62 for the establishment of effective pathogen-specific immunity.

63 lements into CRISPR loci to provide sequence-specific immunity.

64 n that compromise both leukemia and pathogen-specific immunity.

65 ll recovery and transfer of protective virus-specific immunity.

66 ation of latent virus and improvement of HIV-specific immunity.

67 amatic and long-term consequences for tissue-specific immunity.

68 s, thereby obviating the requirement for HIV-specific immunity.

69 mune responses, thereby possibly shaping the specific immunity.

70 at B. burgdorferi exposure may elicit strain-specific immunity.

71 ng CD8 T cell activity and boosting pathogen-specific immunity.

72 ental for the development of robust Borrelia-specific immunity.

73 tigen-specific Tregs and constrained antigen-specific immunity.

74 with multiple genotypes, suggesting genotype-specific immunity.

75 fects for the development of robust Borrelia-specific immunity.

76 ious sites of the Ad fiber to elicit epitope-specific immunity.

77 sease (GVHD) rates, but also impair pathogen-specific immunity.

78 t S. flexneri interferes with the priming of specific immunity.

79 with HIV, but also to recapitulate human HIV-specific immunity.

80 G significantly inhibiting adaptive allergen-specific immunity.

81 for several developmental processes and race-specific immunity.

82 ed immune suppression and facilitating tumor-specific immunity.

83 al inoculation to elicit significant antigen-specific immunity.

84 vaccine design is the phenomenon of "strain-specific" immunity.

85 ance coincided with the development of virus-specific immunity (3-6 weeks postinfection), suggestive

86 s have shown that despite induction of virus specific immunity, a curative response is often not atta

87 s enhanced in mice with established SIINFEKL-specific immunity after AAV2-OVA/alpha1 anti-trypsin (AA

88 Retention of pathogen- and TAA-specific immunity after alloanergization demonstrates th

89 play a crucial role in development of donor-specific immunity after islet transplantation.

90 Reconstitution of CMV-specific immunity after transplant remains a primary cli

91 In addition, the generation of protein-specific immunity, after peptide immunization, was assoc

92 d with LCMV develop a transient defect in Ag-specific immunity against heterologous viral infection.

93 echanism for the induction of potent antigen-specific immunity against malignant cells.

94 ned accurate estimates for the degree of age-specific immunity against monkeypox, influenza A(H5N1) a

95 The need for a paradigm shift from type-specific immunity against S. pyogenes to emm-cluster bas

96 low bacteria and archaea to acquire sequence-specific immunity against selfish genetic elements such

97 n-modulation was accompanied by increased Ag-specific immunity against the neu protein, a self Ag.

98 w that these patterns can arise from cluster-specific immunity alone.

99 on in CD4(+) T cells while maintaining virus-specific immunity, an objective critical in the developm

100 We show that weak serotype-specific immunity and an acquired response not specific

101 ments of virus load, target cells, and virus-specific immunity and applied it to a comprehensive data

102 T cell receptors (TCRs) are key to antigen-specific immunity and are increasingly being explored as

103 virus (EBV) could effectively restore virus-specific immunity and control viral infections.

104 g the RIG-I pathway to enhance viral-vaccine-specific immunity and have broader implications for desi

105 rogrammed cell death 1 (PD-1) activate tumor-specific immunity and have shown remarkable efficacy in

106 future include vaccine development, pathogen-specific immunity and identification of risk factors for

107 human immunodeficiency virus type 1 (HIV-1)-specific immunity and increase clearance of HIV-1-expres

108 y to contribute to the deregulation of tumor-specific immunity and its consequences.

109 , those who succumbed have minimal influenza-specific immunity and little evidence of T-cell activati

110 deletion may contribute significantly to CMV-specific immunity and might therefore also influence chi

111 inactivated influenza vaccine induces strain-specific immunity and must be updated annually.

112 SV) are characterized by short-lasting virus-specific immunity and often long-term airway morbidity,

113 implications for our understanding of tissue-specific immunity and pathologies.

114 oung mice, and MDSC depletion improved tumor-specific immunity and reduced tumor growth in aged mice.

115 n increase in naturally occurring neoantigen-specific immunity and revealed previously undetected hum

116 Here we investigated the HCV-specific immunity and serum levels of soluble CD30 (sCD3

117 CXCL12 and CCL5 in activation of melanocyte-specific immunity and suggest inhibition of these chemot

118 nsitization affect the evolution of filarial-specific immunity and susceptibility to W. bancrofti inf

119 We investigated the antigen-specific immunity and T-cell memory generated by a prime

120 ation of antiretroviral therapy (ART) on HIV-specific immunity and the balance of the CD4(+) T-cell t

121 results improve our understanding of subtype-specific immunity and the neutralization breadth require

122 nal effects of these cytokines on innate HIV-specific immunity and their impact on cells harboring HI

123 le for dendritic cells in initiating antigen-specific immunity and tolerance.

124 (DT)-mediated Treg depletion improved tumor-specific immunity and was clinically effective only in y

125 roles in settings of inadequate or impaired specific immunity, and acquired alterations in the level

126 safety, successful in vivo induction of PSA-specific immunity, and impact on surrogate clinical endp

127 lls in an MLR, inducing human papillomavirus-specific immunity, and migrating from epidermal tissue.

128 is evidence that irradiation mobilizes tumor-specific immunity, and recent studies showed that the ef

129 -generation MAP immunogens for eliciting LND-specific immunity, and tested them in rabbits.

130 ication-defective viruses to enhance antigen-specific immunity; and (c) the combined use of recombina

131 Initial evaluations of peptide-specific immunity are based on results of chromium relea

132 ogical correlates of hepatitis C virus (HCV)-specific immunity are not well understood.

133 parasite-mediated myocytolysis and parasite-specific immunity, are coincident during active infectio

134 tored the effects of gene deficiencies on PG-specific immunity, arthritis severity, leukocyte traffic

135 is thought to limit late stages of pathogen-specific immunity as a means of minimizing associated ti

136 Using cytomegalovirus (CMV)-specific immunity as a paradigm, we evaluated the status

137 This implies that pathogen-specific immunity at mucosal sites is critical for the c

138 h might have skewed our understanding of CMV-specific immunity at older ages.

139 a paradigm shift in our understanding of HCV-specific immunity at the MFI as well as novel insights i

140 he generation of effective levels of antigen-specific immunity at the mucosal sites of pathogen entry

141 ation was made between the presence of tumor-specific immunity at the time of diagnosis and overall s

142 umor cells leads to the development of tumor-specific immunity, because cured mice are immune to the

143 ach animal correlated with the levels of Gag-specific immunity before virus challenge.

144 titer CMVIG preparations provide passive CMV-specific immunity but also exert complex immunomodulator

145 s-infected immature DCs would activate virus-specific immunity, but facilitating virus dissemination.

146 ammatory cytokines but also directly affects specific immunity by differentiating monocytes into macr

147 events was likely due to inhibition of donor-specific immunity by the immunosuppressive regimen.

148 sized that IRX-2 enhanced tumor antigen-(TA)-specific immunity by up-regulating functions of dendriti

149 We have shown that: 1) TS-specific immunity can protect against acute T. cruzi inf

150 e evidence of partial type-specific or clade-specific immunity conferred by seropositivity to HPV 16

151 Potent HIV-specific immunity could be achieved by efficient priming

152 d on: establishing the longevity of poxvirus-specific immunity, defining key immune epitopes targeted

153 CM-specific immunity did not cross-react with donor antigen

154 Preexisting Invaplex-specific immunity did not interfere with the capacity to

155 etent host by suppressing heterologous virus-specific immunity during aging.

156 ic cells participate in the generation of Ag-specific immunity during infection.

157 ferences in humoral and T cell-mediated MUC1-specific immunity elicited in human MUC1-transgenic (Tg)

158 ion as an approach to initiate local antigen-specific immunity, enhance previously existing systemic

159 nd the treatment-mediated promotion of tumor-specific immunity, especially the antitumor CD8(+) T-cel

160 Whether HERV-specific immunity exists in vertically HIV-1-infected ch

161 ial subunit vaccine to provide variant cross-specific immunity for African trypanosomiasis.

162 hock protein 70 (HSP70) on the potency of Ag-specific immunity generated by a Sindbis virus self-repl

163 t of linkage to FL on the potency of antigen-specific immunity generated by naked DNA vaccines admini

164 protein 70 (HSP70) on the potency of antigen-specific immunity generated by naked DNA vaccines.

165 hin these DNAs suggests that most or all fat-specific immunity genes contain a common organization of

166 enon termed "memory inflation." Elevated CMV-specific immunity has been correlated with an increased

167 This autologous specific immunity has been demonstrated using a number o

168 , consistent and lasting generation of tumor-specific immunity has been rarely demonstrated.

169 Because M2e-specific immunity has been shown to decrease morbidity a

170 es that are based on heterotypic or serotype-specific immunity has prompted many countries to establi

171 Time to development of detectable HER-2/neu-specific immunity, however, was significantly earlier fo

172 Vaccination of individuals with existing HIV-specific immunity improved the magnitude, breadth, and p

173 ction and VZV reactivation, we characterized specific immunity in 207 nonsymptomatic immunocompetent

174 ns capable of inducing antiviral CD8+ T-cell-specific immunity in a manner compatible with human deli

175 S-936559 infusions appeared to enhance HIV-1-specific immunity in a subset of participants.

176 , 4 years after clearance, regulation of HCV-specific immunity in blood by regulatory T cells (Tregs)

177 To model HIV-specific immunity in breast milk, lactation was pharmaco

178 plications for understanding the role of CEA-specific immunity in human colon cancer patients and sug

179 Influenza-specific immunity in humans is unique because there are

180 Although effective in inducing tumor-specific immunity in mice and in some clinical trials, t

181 naive mice had no impact on priming antigen-specific immunity in mice immunized with a recombinant L

182 contribute to defective peptide:MHC class II-specific immunity in neonates.

183 The development of vaccines to induce tumor-specific immunity in patients with cancer has as emerged

184 or with CY and DOX is safe and induces HER2-specific immunity in patients with metastatic breast can

185 sults demonstrate that the presence of FVIII-specific immunity in recipients does not negate engraftm

186 th particular DCs for efficient induction of specific immunity in the absence of additional adjuvant.

187 ted larval stages produces a substantial and specific immunity in the absence of egg-induced patholog

188 1 permits the slow development of Leishmania-specific immunity in the absence of open ulcers.

189 Here we provide evidence for acquired strain-specific immunity in the crustacean Daphnia magna infect

190 a safe and efficient means to restore virus-specific immunity in the immunocompromised host.

191 r surface protein C (OspC), at the advent of specific immunity in the mammalian host.

192 alaria, its impact on development of malaria-specific immunity in these children remains poorly under

193 red mechanisms leading to this change in EBV-specific immunity in untreated patients with MS and heal

194 icient, neutrophil supernatant attenuated Ag-specific immunity in vivo.

195 ing immune pathology without compromising Ag-specific immunity in vivo.

196 ding, the development of effective, pathogen-specific immunity in young mice requires alphabeta T cel

197 component of gene expression for innate and specific immunity, in the hematopoietic system, in cellu

198 fferential upregulation of influenza vaccine-specific immunity including hemagglutination inhibition

199 Vaccine-induced HIV-specific immunity, including response rate, magnitude, a

200 attenuated virus, nor WT mice with Th2 RABV-specific immunity induced by immunization with inactivat

201 gies of vaccination can enhance the level of specific immunity induced by nucleic acid vaccines.

202 To determine whether antigen-specific immunity influences the creation, expansion, or

203 Organ-specific immunity is a feature of many infectious diseas

204 Specific immunity is a layer of defense exquisitely broa

205 ived virus-specific T cells to restore virus-specific immunity is an effective strategy to control CM

206 Pretreatment HCV-specific immunity is associated with response to combina

207 o rickettsiae and that generation of antigen-specific immunity is crucial to complete protection.

208 Understanding how pathogen-specific immunity is elicited while avoiding inappropria

209 Thus, tumor-specific immunity is inducible by the combination of LC

210 Enhancement of HIV-specific immunity is likely required to eliminate latent

211 st acute T. cruzi infection; 2) effective TS-specific immunity is maintained during chronic T. cruzi

212 We conclude that antigen-specific immunity is not involved in the initiation, exp

213 Induction of a long-term tumor-specific immunity is the ultimate cure of metastatic can

214 s diversity has led to concerns about allele-specific immunity limiting the effectiveness of vaccines

215 es, DBP allelic variation eliciting a strain-specific immunity may be a major challenge for developme

216 Enhanced human immunodeficiency virus (HIV)-specific immunity may be required for HIV eradication.

217 In addition, a limited virus-specific immunity may contribute to HCV persistence.

218 ytoma models, it is still unclear whether Id-specific immunity may play a role in the regulation of t

219 Overcoming this defect in EBV-specific immunity may prevent or enhance treatment of EB

220 enhance and/or restore the function of virus-specific immunity may protect from disease progression.

221 abine and an agonist of CD40 to induce tumor-specific immunity mediated by T cells.

222 ceiving the highest dose developed HER-2/neu-specific immunity more rapidly than those who received t

223 Leishmania-specific immunity observed 5 weeks after infection in rL

224 represents an attractive target for antigen-specific immunity of cervical cancer.

225 unotherapeutic approach to augment the HIV-1-specific immunity of infected patients.

226 he impact of preexisting cardiac myosin (CM)-specific immunity on murine heart transplant recipients

227 doses during infancy did not affect serotype-specific immunity or carriage.

228 tical ridge that correlated with alloantigen-specific immunity or immune tolerance.

229 g the first 3 months and those with poor CMV-specific immunity or low CD4 counts.

230 maRs on human DCs to generate either antigen-specific immunity or tolerance.

231 In mice with preexisting L. monocytogenes-specific immunity, priming of naive T cells was not prev

232 id (TT) immunity by quantifying age- and sex-specific immunity prior to and 2 years after introductio

233 We investigated the ability of each colicin-specific immunity protein (Im2, Im7, Im8 and Im9) to bin

234 lting in growth inhibition or death unless a specific immunity protein is present.

235 toxins into neighboring bacteria and produce specific immunity proteins that protect against self-int

236 tion mechanism explains the ability of DNase-specific immunity proteins to display dual recognition s

237 themselves from autoinhibition by producing specific immunity proteins.

238 e and appears to be due to a defect in HIV-1-specific immunity rather than infection with attenuated

239 al health, the target antigens of Salmonella-specific immunity remain poorly defined.

240 the cellular dynamics that lead to pathogen-specific immunity remain poorly understood.

241 ction to limit the recall responses of tumor-specific immunity, remain poorly understood and interfer

242 Induction of tumor-specific immunity requires that dendritic cells (DCs) ef

243 es the efficiency with which proteins elicit specific immunity, setting the stage for proof-of-concep

244 Pathogen-specific immunity showed age-appropriate levels of endem

245 lso relies on the systemic spread of a virus-specific immunity signal.

246 vation of dendritic cells and enhancement of specific immunity, similar to selected synthetic dsRNA m

247 Serotype-specific immunity stabilizes competition, and acquired i

248 This boost and loss of TAA-specific immunity suggests that virtually every donor ha

249 ter intrinsic capacity to reconstitute HIV-1-specific immunity than adults, and may be excellent cand

250 gainst tissue of solid organs leads to organ-specific immunity that can be transferred by DLI was unk

251 an be used as a tumor vaccine to elicit DKK1-specific immunity that can control myeloma growth or eve

252 ered dendritic cells (DC) generate strong Ag-specific immunity that has an absolute requirement for b

253 C6VL-DC vaccines stimulated potent tumor-specific immunity that protected mice against lethal cha

254 c vaccination often induces markers of tumor-specific immunity, therapeutic responses remain rare.

255 to explore the possibility of inducing tumor-specific immunity through active immunization in the abs

256 in binding portion of coagulases confer type-specific immunity through the neutralization of S. aureu

257 Interventions to enhance tumor-specific immunity through vaccination, sustaining effect

258 proposed as a strategy that could boost HIV-specific immunity, through controlled exposure to autolo

259 tor-ligand interaction and propose that host-specific immunity to a particular Gram-negative bacteriu

260 h the known 3- to 6-month lag in recovery of specific immunity to CMV after initiating cART and sugge

261 be predicted to confer a high degree of type-specific immunity to EOD to their infants.

262 n to influence the development of Salmonella-specific immunity to infection in vivo.

263 e also examined the contribution of T. cruzi-specific immunity to inflammation by injection of T. cru

264 med autologous T-cell product in stimulating specific immunity to influenza.

265 be interaction that innately offers serotype-specific immunity to IPD.

266 t seems to wax and wane on the importance of specific immunity to malignant cell antigens by previous

267 of the mucosal immune system, confer antigen-specific immunity to mucosally acquired pathogens.

268 derstanding if oral vaccination provides non-specific immunity to other infections so that the conseq

269 vDBPII antibodies are associated with strain-specific immunity to P. vivax and support the use of PvD

270 VSTs) is a strategy to rapidly restore virus-specific immunity to prevent or treat viral diseases aft

271 examined whether individuals acquired strain-specific immunity to PvDBPII.

272 indicate that Hsp70.PC-F vaccine can induce specific immunity to radioresistant populations of mamma

273 Serotype-specific immunity to Streptococcus pneumoniae is conferr

274 complete regression of metastatic tumor and specific immunity to subsequent rechallenge in the major

275 nks the role of the microbiota and microbial-specific immunity to the development of murine SGVHD.

276 demonstration that there is infection stage-specific immunity to tuberculosis has implications for v

277 -Cas adaptive immune system confers sequence-specific immunity to viral infection and has the potenti

278 eptibility to W. bancrofti and skews filaria-specific immunity toward a Th2-type cytokine response.

279 cy of the passive transfer of protective HSV-specific immunity under conditions of acute psychologica

280 containment and may support induction of HBV-specific immunity upon HBV infection, but may also contr

281 ts, the molecular mechanisms underpinning Ag-specific immunity upon vaccination remain unclear.

282 The induction of PSA-specific immunity was also evaluated.

283 Carrier-protein specific immunity was also shown to be effective in redu

284 Polyfunctional CMV-specific immunity was assessed by stimulating peripheral

285 However, pp65-specific immunity was crucial for controlling viral diss

286 city and both cellular and humoral HER-2/neu-specific immunity was evaluated.

287 pes virus and tumor-associated antigen (TAA)-specific immunity was measured with HLA-class I-restrict

288 In conclusion, C. hominis-specific immunity was sufficient to completely protect a

289 Gag-specific immunity was sufficiently potent to protect aga

290 e that dbp allelic diversity plays in strain-specific immunity, we examined the ability of an anti-Sa

291 immune enhancement (e.g. tumor- and pathogen-specific immunity), whereas boosting these factors will

292 n direct tumor cell death and augments tumor-specific immunity, which enhances tumor control both loc

293 We hypothesized that antitumor-specific immunity, which is induced by interleukin (IL)

294 herapeutics, with the goal of inducing tumor-specific immunity while preventing premature virus clear

295 vaccine approaches is that preexisting HIV-1-specific immunity will block or reduce infection.

296 ming by innate immune cells induces pathogen-specific immunity with long-term protection.

297 Boosting MUC1-specific immunity with vaccines, especially effector mec

298 hin 7-9 months (between epidemics) and group-specific immunity within 2-4 months (during an epidemic

299 primary infection, some infants lose strain-specific immunity within 7-9 months (between epidemics)

300 ones, provides a means of augmenting antigen-specific immunity without the in vivo constraints that c